Monitor for Form 4 filings to confirm whether the sale was executed. A director's routine option exercise and sale is not a red flag; no further action warranted unless followed by a cluster of insider sales.
Price Chart
Executive Summary
Director Anne O'Riordan filed a Form 144 notice of intent to sell 14,687 shares of Jazz Pharmaceuticals common stock, with an estimated aggregate market value of approximately $3.36 million. The shares are to be sold through Morgan Stanley Smith Barney and were acquired via stock option exercise on the same day. This is a routine insider sale by a non-executive director, representing a modest portion of her holdings, and is not indicative of operational concerns.
Key Facts
- Director Anne O'Riordan filed Form 144 on 2026-10-08 to sell 14,687 shares.
- Estimated aggregate market value of the proposed sale is $3,356,713.85.
- Shares were acquired via stock option exercise on the same date (2026-10-08).
- Broker: Morgan Stanley Smith Barney LLC Executive Financial Services.
- The sale is a routine diversification move by a director, not an executive officer.
Financial Impact
Proposed sale of 14,687 shares valued at approximately $3.36 million, representing a small fraction of the issuer's market cap (not specified but likely <0.1%).
Risk Factors
- Insider sale could signal personal liquidity needs rather than company outlook, but the small size relative to market cap limits concern.
- If additional insiders file similar 144s in the coming weeks, it could indicate broader insider sentiment shift.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-010116 |
| Document: 0001950047-26-010116-index.html | 0001950047-26-010116 |
| Document: 0001950047-26-010116.txt | 0001950047-26-010116 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 6d ago | Press Release | $213.76 $211.97 | ▼ −0.84% | ▼ −1.36% | $210.99 (−1.30%) |
Oct 9, 2026 17d ago | 8-K | $218.42 $216.75 | ▼ −0.76% | ▼ −0.70% | $210.99 (−3.40%) |
Oct 8, 2026 17d ago | 144 | $218.42 $216.75 | ▼ −0.76% | ▼ −0.70% | $210.99 (−3.40%) |
Oct 6, 2026 19d ago | 144 | $231.19 $222.45 | ▼ −3.78% | ▼ −3.36% | $210.99 (−8.74%) |
Oct 1, 2026 24d ago | 144 | $235.67 $236.04 | ▲ +0.16% | ▼ −0.52% | $210.99 (−10.47%) |
Sep 15, 2026 5w ago | 8-K | $240.83 $243.59 | ▲ +1.15% | ▲ +1.59% | $210.99 (−12.39%) |
Sep 14, 2026 5w ago | Insider Cluster | $240.83 $243.59 | ▲ +1.15% | ▲ +1.59% | $210.99 (−12.39%) |
Sep 10, 2026 6w ago | Insider Cluster | $245.80 $245.87 | ▲ +0.03% | ▲ +0.47% | $210.99 (−14.16%) |
Sep 2, 2026 7w ago | Insider Cluster | $247.57 $246.81 | ▲ +0.30% | ▼ −0.08% | $210.99 (+14.78%) |
Aug 31, 2026 7w ago | 144 | $243.71 $245.57 | ▲ +0.76% | ▲ +0.32% | $210.99 (−13.43%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers